The certification validates xCures’ commitment to rigorous foundational cybersecurity controls and information risk management.

xCures AI Platform transforms medical records into actionable insights to improve patient outcomes.

Newton will discuss leveraging artificial intelligence to effectively deliver guideline-recommended care in telemedicine at the premier digital health event.

Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs, and technology executives.

Investigational cancer treatment with the potential to slow brain tumor growth is now available for patients with relapsed/refractory glioblastoma.

Collaboration will focus on analyzing and improving guidelines-based utilization of precision medicine to better support oncologists and cancer patients.

The partnership will empower patients with greater control over their health data and accelerate the discovery and approval of new treatments for kidney cancer.

xCures' patient-centric platform enables outcomes monitoring and evidence generation, providing insights into the best treatments, including for rare cancers.

USPTO awards patent for AI tech enabling virtual trials, enhancing clinical decisions through continuous learning from patient experiences.

The company’s platform expansion transforms the value of US healthcare data by harnessing real-time, regulatory-grade data in any therapeutic area to efficiently understand the complex medical histories of patients and drive research through detailed, longitudinal datasets.

Partnership now includes access to five comprehensive oncology datasets, enhancing real-world evidence in cancer research.

AWS cloud configurations will help xCures customers to leverage the company’s robust data gathering and structuring services while maintaining secure, private ownership of their data.

xCures offers unparalleled access to data and the xINFORM patient portal to accelerate pancreatic cancer research and improve patient care OAKLAND, CA - xCures, a leader in real-time clinical data technology, is thrilled to announce a pivotal partnership with the Pancreatic Cancer Action Network (PanCAN).

New study will collect, organize, and share data for Diffuse Midline Glioma (DMG) and Diffuse Intrinsic Pontine Glioma (DIPG) research.

Seamless integration with existing healthcare infrastructures drives unprecedented possibilities to improve medical research and patient care.

xCures data deemed fit-for-purpose to address research questions relevant to the prevention, clinical care, diagnostics, and treatment in oncology.

xCures’ technology harnesses real-time patient data and makes it accessible for scientific exploration and to improve patient options.

CureMatch will leverage the xCures technology that automatically creates a comprehensive outline of a cancer patient’s medical history in order to improve treatment recommendations.

Real-world patient data gives valuable insights, such as collecting data on rare cancers and showing real-world side effects of treatment combinations.

Genome Medical and xCures have joined forces to provide patients with a new level of personalized care.

RenovoRx's Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life.

xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative.

XCELSIOR registry showcases its power in using real-world datasets and clinical outcomes to aid decision-making and treatment options for CNS cancer patients.

Recent changes to patients’ data rights enable xCures’ platform to automatically retrieve patient medical records from institutions and generate powerful care summaries.

xCures partners with mProbe, to leverage their targeted proteomics platform for profiling individual patients' cancer tissues for actionable drug targets xCures, Inc.

Oblato’s first-in-class small molecular OKN-007 will be available through a newly opened compassionate use protocol.

xCures and Vault Health integration creates a decentralized platform to benefit pancreatic cancer research and facilitate enrollment in Faeth’s NEAAR-001 study xCures, Inc.

Decentralized clinical trial for patients with advanced carcinomas helps determine their cancer’s response to specific drugs [EIN Presswire, July 19, 2022] xCures, Inc.

Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients [EIN PressWire June 21, 2022] xCures, Inc.

The new collaboration focuses on improving outcomes by continuous learning from every patient’s journey across diverse datasets CHICAGO, IL, UNITED STATES, June 3, 2022 /EINPresswire/  Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access and insights for life science companies across multiple use cases.

Members of CDRC will be able to utilize xCures’ technology to quickly abstract and structure clinical data to support drug repurposing studies in rare cancer.

xCures to use tumor sequencing information and its platform to pair patients with available treatment options Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor's clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile.

Oncologist and cancer educator Dr.

– 240 million Americans can play a vital role in the search for a vaccine or treatment by contributing critical data from home – SAN FRANCISCO – April 15, 2020 – xCures, a health technology company focused on the use of artificial intelligence, has released preliminary data from the company’s Behavior, Environment, And Treatments for COVID-19 (BEAT19) registry study, NCT04321811.